Next Article in Journal
The Role of Oxidative Stress and Antioxidants in Liver Diseases
Next Article in Special Issue
Genome Editing in C. elegans and Other Nematode Species
Previous Article in Journal
Evaluation of New Fluorescent Lipophosphoramidates for Gene Transfer and Biodistribution Studies after Systemic Administration
Previous Article in Special Issue
Minimizing off-Target Mutagenesis Risks Caused by Programmable Nucleases
Open AccessReview

Application of CRISPR/Cas9 Technology to HBV

National Center for Clinical Laboratories, Beijing Hospital, Beijing 100730, China
*
Author to whom correspondence should be addressed.
Academic Editor: Izuho Hatada
Int. J. Mol. Sci. 2015, 16(11), 26077-26086; https://doi.org/10.3390/ijms161125950
Received: 8 September 2015 / Revised: 25 October 2015 / Accepted: 26 October 2015 / Published: 2 November 2015
(This article belongs to the Special Issue Genome Editing)
More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (cccDNA), which acts as a transcription template for viral mRNA and pre-genomic RNA synthesis and secures virus persistence. Thus, the fact that only a small number of patients treated achieve sustained viral response (SVR) or cure, highlights the need for new therapies against HBV. The clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system can specifically target the conserved regions of the HBV genome. This results in robust viral suppression and provides a promising tool for eradicating the virus. In this review, we discuss the function and application of the CRISPR/Cas9 system as a novel therapy for HBV. View Full-Text
Keywords: CRISPR/Cas9; HBV; cccDNA; antiviral CRISPR/Cas9; HBV; cccDNA; antiviral
Show Figures

Figure 1

MDPI and ACS Style

Lin, G.; Zhang, K.; Li, J. Application of CRISPR/Cas9 Technology to HBV. Int. J. Mol. Sci. 2015, 16, 26077-26086.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop